Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
University of California, Davis
Hoffmann-La Roche
Sun Yat-sen University
Sun Yat-sen University
GOG Foundation
University Health Network, Toronto
Hoffmann-La Roche
National Cancer Institute (NCI)
Yale University
Duke University
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
USWM, LLC (dba US WorldMeds)
University of Colorado, Denver
Institute of Cancer Research, United Kingdom
M.D. Anderson Cancer Center
EMD Serono
Yale University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
University of Oklahoma
M.D. Anderson Cancer Center
AstraZeneca
Haihe Biopharma Co., Ltd.
ARCAGY/ GINECO GROUP
AstraZeneca
M.D. Anderson Cancer Center
University of Oklahoma
ImmunityBio, Inc.
Canadian Cancer Trials Group
Hoffmann-La Roche
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
OHSU Knight Cancer Institute
City of Hope Medical Center
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brigham and Women's Hospital
H. Lee Moffitt Cancer Center and Research Institute
UNC Lineberger Comprehensive Cancer Center
Verastem, Inc.